KPV is a short C-terminal α-MSH tripeptide known for anti-inflammatory and gut-healing effects, run in the community mainly for systemic inflammation and pain, gut and digestive issues, and skin and wound healing, with gut healing drawing the most satisfied reports. People most commonly dose 2 mg a day, mostly daily, while clinician protocols run lower at 200 to 500 mcg twice daily by subcutaneous injection over four-to-eight-week cycles. Mild GI effects are the most frequently reported experience and skew positive; flush, sleep, and fluid-retention effects surface only occasionally. There is no FDA-approved indication, so all use is off-label or compounded.
Data last updated
Measured on 4 of 6 axes
Evidence shape
KPV currently exists as an animal-only research peptide, with all available evidence derived from preclinical and mechanistic studies. There are no published human trials or registered clinical studies to support its use for any indication. Because the existing data is limited to laboratory models, there is no established human safety profile, dosage data, or evidence of efficacy in clinical settings. The absence of human-grade research means that any application of this peptide remains entirely speculative and lacks the validation provided by formal clinical investigation.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How KPV is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Most community users do not specify a schedule, but when they do they typically take about 2 mg; among those who give a frequency, daily dosing (~2 mg) is most common (13 reports), with smaller groups using twice‑daily (~500 mcg) or weekly (~10 mg) regimens, and no cycling is reported.